𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II Trial of Hyperfractionated Accelerated Split-Course Radiochemotherapy with 5-FU and Cis-DDP in Advanced Head and Neck Cancer

✍ Scribed by Antje Ernst-Stecken; Gerhard Grabenbauer; Heinrich Iro; Ludwig Plasswilm; Rolf Sauer

Publisher
Springer
Year
2004
Tongue
German
Weight
331 KB
Volume
180
Category
Article
ISSN
0179-7158

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Neurotoxicity in a phase I trial of cont
Neurotoxicity in a phase I trial of continuous-infusion cisplatin with hyperfractionated radiotherapy for locally advanced head and neck cancer
✍ Gerald H. Clamon; Lynn Baatz; Henry T. Hoffman; David H. Hussey; Matthew Glascoc πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 569 KB

## Background: Both twice daily fractionated radiotherapy and concurrent cisplatin with once-daily radiotherapy have been shown to improve local disease control in patients with head and neck cancer. the objective of this phase i trial was to determine the maximum tolerated dose of cisplatin which

Toxicity and outcome analysis of patient
Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies
✍ Noel M. Kramer; Eric M. Horwitz; Jonathan Cheng; John A. Ridge; Steven J. Feigen πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 205 KB πŸ‘ 2 views

## Abstract ## Background. Patients with local recurrences or new head and neck primary tumors in previously irradiated tissues have few options for salvage treatment. One option for select patients is to undergo reirradiation with concurrent chemotherapy. The purpose of this study is to report th

Phase II clinical trial of parenteral hy
Phase II clinical trial of parenteral hydroxyurea and hyperfractionated, accelerated external beam radiation therapy in patients with advanced squamous cell carcinoma of the head and neck: Toxicity and efficacy with continuous ribonucleoside reductase inhibition
✍ Jonathan J. Beitler; Richard V. Smith; Randall P. Owen; Carl E. Silver; Madhu Ma πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 398 KB πŸ‘ 2 views

## Abstract ## Background Almost all concurrent chemoradiation regimens for head and neck are platinum based; however, cisplatin is associated with severe renal, oto‐, and neurotoxicity. Hydroxyurea (HU) has been associated with fewer irreversible toxicities. We obtained HU in parenteral form to b